As shown in Fig. 1, pan-cancer analysis results showed that RUNX1 increased significantly in 58 datasets, especially those of leukemia, head and neck cancer, colorectal cancer, kidney cancer, and breast cancer. Here, RUNX1 is linked to breast cancer.